Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare ConferencePRNewsWire • 06/07/21
Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational AutoimmunityPRNewsWire • 05/20/21
Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC)PRNewsWire • 05/18/21
Nektar Therapeutics (NKTR) CEO Howard Robin on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/07/21
Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to DeclineZacks Investment Research • 04/29/21
Nektar to Announce Financial Results for the First Quarter 2021 on Thursday, May 6, 2021, After Close of U.S.-Based Financial MarketsPRNewsWire • 04/27/21
Nektar (NKTR) Down 10.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/27/21
Nektar Therapeutics (NKTR) CEO Howard Robin on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/26/21
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial MarketsPRNewsWire • 02/18/21
Nektar Therapeutics Secures $150M From SFJ Pharma For New Study With BEMPEG/Pembrolizumab Combo In Head & Neck CancerBenzinga • 02/17/21